Please login to the form below

Not currently logged in
Email:
Password:

Glassia

This page shows the latest Glassia news and features for those working in and with pharma, biotech and healthcare.

Shire receives FDA nod for self-infusion of Glassia

Shire receives FDA nod for self-infusion of Glassia

Shire's emphysema therapy Glassia has received FDA approval for an expanded label, marking the first time that patients can self-infuse at home. ... Glassia, an alpha-1 proteinase inhibitor, is licensed for the treatment of adults with emphysema due to

Latest news

  • Scratching the surface

    UK. Alpha-1 proteinase inhibitor. Glassia (Baxter International)  . Overt hepatic encephalopathy (HE) recurrence.

  • Biologics buoyant

    52 . Kamada/Baxter. Glassia (liquid Alpha-1 Antitrypsin; AAT) – AAT deficiency (US, Canada, Australia and New Zealand)  . FDA approved. 45. Marina Biotech/Cypress Bioscience. Carbetocin (nasal oxytocin analogue)  - autism.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics